Abstract
Cotrimoxazole (trimethoprim-sulfamethoxazole) is a combination antimicrobial that is frequently used to treat a wide variety of infections. Only recently has hyperkalaemia been recognised as a relatively common complication of therapy with trimethoprim. Hyperkalaemia has been demonstrated to occur with the administration of both high and standard dosages of trimethoprim.
The recognition of this disorder of potassium homeostasis prompted the investigation and ultimate description of the mechanism by which trimethoprim causes hyperkalaemia. Trimethoprim was found to reduce renal potassium excretion through the competitive inhibition of epithelial sodium channels in the distal nephron, in a manner identical to the potassium-sparing diuretic amiloride. Increased risk for hyperkalaemia with trimethoprim treatment appears to be related to both higher dosages and underlying renal impairment. It is probable that other disturbances in potassium homeostasis, such as hyopoaldosteronism and treatment with medications that impair renal potassium excretion, are also risk factors for hyperkalaemia with trimethoprim therapy.
Prevention of this adverse reaction depends upon recognition of patients at risk of developing hyperkalaemia as well as proper dosage selection of trimethoprim for the patient’s prevailing glomerular filtration rate. Management of hyperkalaemia often mandates discontinuation of the drug, volume repletion with isotonic fluids, and other therapies specific to hyperkalaemia. In circumstances where continued treatment with trimethoprim is required, induction of high urinary flow rates with intravenous fluids and a loop diuretic, as well as alkalinisation of the urine, have been shown to block the antikaliuretic effect of trimethoprim on distal nephron cells.
Similar content being viewed by others
References
Lawson DH, Jick H. Adverse reactions to co-trimoxazole. Am J Med Sci 1978; 275: 53–7
Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982; 4: 426–8
Jawetz E. Sulfonamides and trimethoprim. In: Katzung BG, editor. Basic and clinical pharmacology. 2nd ed. Los Altos, California: Lange, 1984: 554–8
Lawson DH, Paice BJ. Adverse reactions to trimethoprim-sulfamethoxazole. Rev Infect Dis 1982; 4: 429–33
Richmond JM, Whitworth JA, FairleyKF, et al. Co-trimoxazole nephrotoxicity [letter]. Lancet 1979; I: 493
Cryst C, Hammar SP. Acute granulomatous interstitial nephritis due to co-trimoxazole. Am J Nephrol 1988; 8: 483–8
Berglund F, Killander J, Pompeius R. Effect of trimethoprimsulfamethoxazole on the renal excretion of creatinine in man. J Urol 1975; 114: 802–8
Choi MJ, Fernandez PC, Coupaye-Gerard B, et al. Trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993; 328: 703–6
Velçzquez H, PerazellaMA,Wright FS, et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119: 296–301
Greenberg S, Reiser IW, Chou SY, et al. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119: 291–5
Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996; 46: 187–92
Kaufman AM, Hellman G, Abramson RG. Renal salt wasting and metabolic acidosis with trimethoprim-sulfamethoxazole therapy. Mt Sinai J Med 1983; 50: 238–9
Kalin MF, Poretsky L, Seres DS, et al. Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome. Am J Med 1987; 82: 1035–8
Medina I,Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl JMed 1990; 323: 776–82
Canaday DH, Johnson JR. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. Ann Intern Med 1994; 120: 437–8
ModestGA, Price B,Mascoli N. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole [letter]. Ann Intern Med 1994; 120: 437
Pennypacker LC, Mintzer J, Pitner J. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole [letter]. Ann Intern Med 1994; 120: 437
Smith GW, Cohen SB. Hyperkalemia and non-oliguric renal failure associated with trimethoprim. BMJ 1994; 308: 454
Marinella MA. Reversible hyperkalemia associated with trimethoprim-sulfamethoxazole. Am J Med Sci 1995; 310: 115–9
Alappan R, Perazella MA, Buller GK Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124: 316–20
21 Bugge JF. Severe hyperkalemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs. J Intern Med 1996; 240 249–52
Elisaf M, Terrovitou C, Tomos P, et al. Severe hyperkalemia after cotrimoxazole administration in a patient with hyporeninemic hypoaldosteronism. Nephrol Dial Transplant 1997; 12: 1254–5
Safrin S, Finkelstein DM. Comparison of oral agents for the treatment of Pneumocystis carinii pneumonia [letter]. Ann Intern Med 1997; 126: 407–8
Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: Is hyperkalemia a significant problem? Am J Nephrol 1999; 19 (3): 389–94
Funai N, Shimamoto Y,MatsuzakiM, et al. Hyperkalemia with renal tubular dysfunction by sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy. Haematologia 1993; 25: 137–41
Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1996; 124: 792–802
Perazella MA. Comparison of oral agents for the treatment of Pneumocystis carinii pneumonia [letter]. Ann Intern Med 1997; 126: 407
Reiser IW, Chou S, Brown MI, et al. Reversal of trimethopriminduced antikaliuresis. Kidney Int 1996; 50: 2063–9
Schreiber M, Schlanger LE, Chen CB, et al. Antikaliuretic action of trimethoprim isminimized by raising urine pH.Kidney Int 1996; 49: 82–7
Eiam-ong S, Kurtzman NA, Sabatini S. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int 1996; 49: 1372–8
Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J Gen Intern Med 1997; 12: 646–56
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perazella, M.A. Trimethoprim-Induced Hyperkalaemia. Drug-Safety 22, 227–236 (2000). https://doi.org/10.2165/00002018-200022030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200022030-00006